The global HIV response has made tremendous progress but is entering a new phase with
additional challenges. Scientific innovations have led to multiple safe, effective, and durable …

The effectiveness of HIV pre-exposure prophylaxis (PrEP) hinges on adherence, which has
been restricted by multifaceted barriers. Uptake of PrEP has been impeded by poor access …

An effective HIV-1 vaccine is a global health priority but has remained elusive for more than
40 years. Key scientific hurdles that have hampered vaccine development are the …

Background As set out in Sustainable Development Goal 3.3, the target date for ending the
HIV epidemic as a public health threat is 2030. Therefore, there is a crucial need to evaluate …

Clinical trials provide evidence that pre-exposure prophylaxis (PrEP) prevents HIV
acquisition including through sharing of injection equipment among people who inject drugs …

We used group-based trajectory models to identify 4 distinct trajectory patterns of adherence
to preexposure prophylaxis (PrEP) among 20 696 users. Only 44.5% were consistently PrEP …

Implementation of pre-exposure prophylaxis (PrEP) to prevent HIV transmission is
suboptimal in the United States, particularly among people who use drugs (PWUD). PrEP …

Introduction HIV pre-exposure prophylaxis (PrEP), in which people take HIV medication to
prevent HIV acquisition, underpins global HIV transmission elimination strategies. Effective …

Men who have sex with men (MSM) is a high-risk population for HIV and sexually
transmitted infections (STIs). Pre-exposure prophylaxis (PrEP) is effective in HIV prevention …

Structural racism and discrimination (SRD) is deeply embedded across US healthcare
institutions, but its impact on health outcomes is challenging to assess. The purpose of this …